NCT06858696 - A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

April 30, 2026

Conditions

Hepatic Insufficiency

Interventions

DRUG

Mavorixafor

Mavorixafor will be administered per schedule specified in the arm description.

Trial Locations (4)

NOT_YET_RECRUITING

Orlando Clinical Research Center, Orlando

RECRUITING

Texas Liver Institute/Alamo Medical Research, San Antonio

NOT_YET_RECRUITING

Catalina Research Institute, LLC, Montclair

RECRUITING

Catalina Research Institute, LLC, Rialto